Chemical Property of Esmolol hydrochloride
Chemical Property:
- Appearance/Colour:white solid
- Melting Point:48-50 °C
- Boiling Point:430.2 °C at 760 mmHg
- Flash Point:214 °C
- PSA：67.79000
- Density:1.026 g/cm3
- LogP:2.72280
- Storage Temp.:−20°C
- Solubility.:H2O: soluble12mg/mL
- Water Solubility.:Slightly soluble
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:5
- Rotatable Bond Count:10
- Exact Mass:331.1550360
- Heavy Atom Count:22
- Complexity:288
- Purity/Quality:
-
99% *data from raw suppliers
Esmolol hydrochloride
*data from reagent suppliers
Safty Information:
- Pictogram(s):
52/53:;
- Hazard Codes:52/53:;
- Statements:
52/53
- Safety Statements:
61
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O.Cl
- Recent ClinicalTrials:The Impact of Esmolol Administration on Postoperative Recovery
- Recent EU Clinical Trials:Prospective, multicenter and open study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments.
-
Description
Esmolol is an ultra-short acting, cardioselective P-blocker with no intrinsic
sympathomimetic activity. The capability of rapid reversal makes esmolol uniquely
suitable for the acute management of supraventricular tachycardia and the control of blood
pressure and heart rate during surgery or other cardiac emergencies.
-
Uses
Cardioselective -adrenergic blocker. Antiarrhythmic Esmolol hydrochloride is indicated for paroxysmal supraventricular tachycardia, the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician's judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. antiarrhytmic;cardioselective beta1 receptor blocker
-
Therapeutic Function
Beta-adrenergic blocker
-
Clinical Use
Beta-adrenoceptor blockerShort-term treatment of supraventricular
arrhythmias (including AF, atrial flutter, sinus
tachycardia)Tachycardia and hypertension in the perioperative
period
-
Drug interactions
Potentially hazardous interactions with other drugsAnaesthetics: enhanced hypotensive effect.Analgesics: NSAIDs antagonise hypotensive effect.Anti-arrhythmics: increased risk of myocardial
depression and bradycardia; with amiodarone,
increased risk of bradycardia and AV block and
myocardial depression; increased risk of myocardial
depression and bradycardia with flecainide.Antidepressants: enhanced hypotensive effect with
MAOIs.Antimalarials: increased risk of bradycardia with
mefloquine.Antipsychotics: enhanced hypotensive effect with
phenothiazinesCalcium-channel blockers: increased risk of
bradycardia and AV block with diltiazem; severe
hypotension and heart failure occasionally with
nifedipine and possibly other dihydropyridines;
asystole, severe hypotension and heart failure with
verapamil - avoid concomitant verapamil use.Antihypertensives: enhanced hypotensive effect;
increased risk of withdrawal hypertension with
clonidine; increased risk of first dose hypotensive
effect with post-synaptic alpha-blockers.Cytotoxics: possible increased risk of bradycardia
with crizotinib.Diuretics: enhanced hypotensive effect.Fingolimod: possibly increased risk of bradycardia.Moxisylyte: possible severe postural hypotension.Sympathomimetics: severe hypertension with
adrenaline and noradrenaline and possibly dobutamine
